Dyadic International (DYAI) Receivables - Net (2017 - 2026)
Dyadic International (DYAI) posted Receivables - Net of $996464.0 for Q1 2026, down 8.61% sequentially from $1.1 million in Q4 2025, and up 349.43% YoY from $221719.0 in Q1 2025.
Dyadic International (DYAI) Receivables - Net (2017 - 2026) Analysis & Trends
Dyadic International has reported Receivables - Net for 10 years, with the latest figure at $996464.0 in Q1 2026.
- Quarterly Receivables - Net rose 349.43% year-over-year to $996464.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $996464.0 (up 349.43% YoY) and the FY2025 annual result came in at $1.1 million, up 359.99% from the prior year.
- Receivables - Net retreated to $996464.0 in Q1 2026 per DYAI's latest filing, from $1.1 million in the prior quarter.
- Over five years, Receivables - Net peaked at $528.2 million in Q1 2022 and troughed at $221719.0 in Q1 2025.
- A 5-year average of $31.6 million and a median of $466159.0 in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net surged 137095.26% in 2022, then plunged 99.86% in 2023.
- Over 5 years, Receivables - Net stood at $330001.0 in 2022, then surged by 41.26% to $466159.0 in 2023, then sank by 49.15% to $237027.0 in 2024, then soared by 359.99% to $1.1 million in 2025, then slipped by 8.61% to $996464.0 in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $996464.0, $1.1 million, and $916574.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 996,464.00 |
| Mar 31, 2026 | 996,464.00 |
| Dec 31, 2025 | 1.09 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 916,574.00 |
| Sep 30, 2025 | 916,574.00 |
| Jun 30, 2025 | 715,317.00 |
| Jun 30, 2025 | 715,317.00 |
| Mar 31, 2025 | 221,719.00 |
| Mar 31, 2025 | 221,719.00 |
| Dec 31, 2024 | 237,027.00 |
| Dec 31, 2024 | 237,027.00 |
| Sep 30, 2024 | 352,934.00 |
| Sep 30, 2024 | 352,934.00 |
| Jun 30, 2024 | 249,806.00 |
| Jun 30, 2024 | 249,806.00 |
| Mar 31, 2024 | 246,138.00 |
| Mar 31, 2024 | 246,138.00 |
| Dec 31, 2023 | 466,159.00 |
| Dec 31, 2023 | 466,159.00 |